Biogen discovers, develops, manufactures, and delivers therapies for neurological and neurodegenerative diseases. Products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis. They also offer ADUHELM for Alzheimers disease, FUMADERM for plaque psoriasis, and RITUXAN for non-Hodgkins lymphoma. The company is developing products for MS, Alzheimers disease, and dementia. Biogen has collaboration agreements with various companies. Founded in 1978, the company is headquartered in Cambridge, Massachusetts.
Indicator | Value |
---|---|
PER | 11.2 |
EV/EBITDA | 7.3 |
Price/Free Cash Flow' | 7.2 |
ROIC | 12.5% |
Net Debt/EBITDA | 1.3 |